Scarica l'app Stockscreener
176.49
0.29%
-0.44
Precedente Chiudi:
$176.93
Aprire:
$175.86
Volume 24 ore:
24,748
Relative Volume:
0.02
Capitalizzazione di mercato:
$8.68B
Reddito:
$4.06B
Utile/perdita netta:
$413.08M
Rapporto P/E:
22.03
EPS:
8.01
Flusso di cassa netto:
$560.48M
1 W Prestazione:
+17.77%
1M Prestazione:
+17.60%
6M Prestazione:
+7.81%
1 anno Prestazione:
-24.44%
Intervallo 1D:
$175.55
$177.27
Intervallo di 1 settimana:
$155.48
$184.17
Portata 52W:
$91.86
$254.15
Charles River Laboratories International Inc Stock (CRL) Company Profile
Nome
Charles River Laboratories International Inc
Settore
Industria
Telefono
781-222-6000
Indirizzo
251 BALLARDVALE ST, WILMINGTON, MA
Confronta CRL con altri titoli
| Azioni | Prezzo | Cap. di mercato | Reddito | Reddito netto | Flusso di cassa | EPS |
|---|---|---|---|---|---|---|
CRL
Charles River Laboratories International Inc
|
176.63 | 8.69B | 4.06B | 413.08M | 560.48M | 8.01 |
|
TMO
Thermo Fisher Scientific Inc
|
476.92 | 180.56B | 43.21B | 6.58B | 6.17B | 17.29 |
|
DHR
Danaher Corp
|
204.00 | 147.13B | 24.01B | 3.41B | 4.86B | 4.70 |
|
IDXX
Idexx Laboratories Inc
|
564.90 | 45.45B | 3.93B | 894.97M | 837.70M | 10.82 |
|
A
Agilent Technologies Inc
|
119.57 | 34.14B | 6.63B | 1.17B | 1.19B | 4.05 |
|
IQV
Iqvia Holdings Inc
|
197.96 | 33.86B | 15.50B | 1.33B | 2.16B | 7.34 |
Charles River Laboratories International Inc Stock (CRL) Upgrades & Downgrades
| Data | Azione | Analista | Modifica della valutazione |
|---|---|---|---|
| 2025-07-09 | Aggiornamento | Citigroup | Neutral → Buy |
| 2025-05-23 | Aggiornamento | Redburn Atlantic | Neutral → Buy |
| 2025-05-14 | Aggiornamento | TD Cowen | Hold → Buy |
| 2025-05-08 | Aggiornamento | Evercore ISI | In-line → Outperform |
| 2025-03-21 | Downgrade | Goldman | Buy → Neutral |
| 2025-03-04 | Aggiornamento | Citigroup | Sell → Neutral |
| 2025-03-03 | Aggiornamento | Redburn Atlantic | Sell → Neutral |
| 2025-01-22 | Downgrade | William Blair | Outperform → Mkt Perform |
| 2025-01-17 | Downgrade | UBS | Buy → Neutral |
| 2024-11-18 | Downgrade | CLSA | Hold → Underperform |
| 2024-11-07 | Aggiornamento | CLSA | Underperform → Hold |
| 2024-10-23 | Iniziato | CLSA | Underperform |
| 2024-10-14 | Iniziato | Redburn Atlantic | Sell |
| 2024-10-07 | Downgrade | Evercore ISI | Outperform → In-line |
| 2024-10-02 | Downgrade | BofA Securities | Buy → Neutral |
| 2024-10-01 | Downgrade | Citigroup | Neutral → Sell |
| 2024-08-08 | Downgrade | JP Morgan | Overweight → Neutral |
| 2024-08-08 | Downgrade | Robert W. Baird | Outperform → Neutral |
| 2024-06-28 | Downgrade | Argus | Buy → Hold |
| 2024-06-07 | Iniziato | Mizuho | Neutral |
| 2024-06-06 | Iniziato | Goldman | Buy |
| 2024-02-15 | Downgrade | Guggenheim | Buy → Neutral |
| 2023-09-13 | Iniziato | TD Cowen | Market Perform |
| 2023-07-10 | Downgrade | Citigroup | Buy → Neutral |
| 2023-02-23 | Aggiornamento | Guggenheim | Neutral → Buy |
| 2023-01-12 | Downgrade | Jefferies | Buy → Hold |
| 2022-09-30 | Aggiornamento | Jefferies | Hold → Buy |
| 2022-08-25 | Iniziato | Credit Suisse | Outperform |
| 2022-08-04 | Downgrade | Morgan Stanley | Overweight → Equal-Weight |
| 2022-05-24 | Iniziato | Guggenheim | Neutral |
| 2022-04-25 | Downgrade | Jefferies | Buy → Hold |
| 2022-04-07 | Iniziato | Stephens | Overweight |
| 2022-02-17 | Reiterato | BofA Securities | Buy |
| 2022-02-17 | Aggiornamento | Citigroup | Neutral → Buy |
| 2022-02-17 | Reiterato | Deutsche Bank | Buy |
| 2022-02-17 | Reiterato | Morgan Stanley | Overweight |
| 2022-02-17 | Reiterato | UBS | Buy |
| 2021-08-05 | Ripresa | Credit Suisse | Neutral |
| 2020-12-16 | Downgrade | Citigroup | Buy → Neutral |
| 2020-09-10 | Aggiornamento | Jefferies | Hold → Buy |
| 2020-07-01 | Aggiornamento | BofA Securities | Neutral → Buy |
| 2020-05-13 | Aggiornamento | UBS | Neutral → Buy |
| 2020-04-21 | Downgrade | Jefferies | Buy → Hold |
| 2020-03-27 | Aggiornamento | Morgan Stanley | Equal-Weight → Overweight |
| 2020-03-02 | Iniziato | Deutsche Bank | Buy |
| 2020-02-18 | Aggiornamento | Wolfe Research | Peer Perform → Outperform |
| 2020-01-10 | Aggiornamento | Goldman | Neutral → Buy |
| 2020-01-08 | Iniziato | Wells Fargo | Overweight |
| 2020-01-07 | Iniziato | Citigroup | Buy |
| 2019-10-18 | Downgrade | BofA/Merrill | Buy → Neutral |
| 2019-06-10 | Iniziato | SVB Leerink | Outperform |
| 2019-04-30 | Ripresa | Evercore ISI | Outperform |
| 2018-12-14 | Iniziato | Deutsche Bank | Buy |
| 2018-10-09 | Iniziato | UBS | Neutral |
| 2018-08-23 | Aggiornamento | Raymond James | Mkt Perform → Outperform |
| 2018-07-17 | Aggiornamento | RBC Capital Mkts | Sector Perform → Outperform |
| 2018-06-15 | Aggiornamento | KeyBanc Capital Mkts | Sector Weight → Overweight |
| 2018-02-14 | Aggiornamento | SunTrust | Hold → Buy |
Mostra tutto
Charles River Laboratories International Inc Borsa (CRL) Ultime notizie
How strong is Charles River Laboratories International Inc. company’s balance sheetTriple-digit returns - jammulinksnews.com
What are Charles River Laboratories International Inc. company’s key revenue driversSky-high profits - jammulinksnews.com
Is Charles River Laboratories International Inc. a growth stock or a value stockUnlock your portfolio’s hidden potential - jammulinksnews.com
What institutional investors are buying Charles River Laboratories International Inc. stockRapid wealth creation - jammulinksnews.com
Is Charles River Laboratories International Inc. a Top Dividend Stock to Watch in 2025Low Risk High Reward Picks - Metal.it
What catalysts could drive Charles River Laboratories International Inc. stock higher in 2025Breakout stock performance - jammulinksnews.com
How Charles River Laboratories International Inc. stock reacts to Fed policy changesSmart Money Trade Setups - Metal.it
How does Charles River Laboratories International Inc. compare to its industry peersGrow your wealth steadily and securely - jammulinksnews.com
What analysts say about Charles River Laboratories International Inc. stockFree Real-Time Stock Data - PrintWeekIndia
What drives Charles River Laboratories International Inc. stock priceExplosive trading opportunities - PrintWeekIndia
Is Charles River Laboratories International Inc. a good long term investmentHigh-profit capital plays - PrintWeekIndia
Charles River Laboratories International Inc. Stock Analysis and ForecastHigh-yield investments - Autocar Professional
Charles River Laboratories Surges 134.22% in Trading Volume, Ranks 365th in Daily Market - AInvest
RPM International Posts Better-Than-Expected Earnings, Joins ICON, MaxLinear, Nasdaq And Other Big Stocks Moving Higher On ThursdayArrive AI (NASDAQ:ARAI), ASGN (NYSE:ASGN) - Benzinga
Charles River Laboratories International Inc. stock outperforms competitors on strong trading day - MarketWatch
Charles River Joins Elly’s Team to Drive Rare Disease Gene Therapy Development - StreetInsider
Charles River Labs Stock Rises on Plasmid DNA Deal with Ellys TeamNews and Statistics - IndexBox
Will Charles River (CRL) Beat Estimates Again in Its Next Earnings Report? - Yahoo Finance
Why Are Charles River Laboratories (CRL) Shares Soaring Today - Yahoo Finance
Why Are Charles River Laboratories (CRL) Shares Soaring Today | Markets | American Financial Group, Inc. - FinancialContent
Charles River Laboratories Surged 8.6% Intraday—Is This a Game-Changer for Biotech Innovation? - AInvest
Here's What to Expect From Charles River Laboratories' Next Earnings Report - MSN
Is it Prudent to Retain Charles River Stock in Your Portfolio Now? - MSN
Agree To Purchase Charles River Laboratories International At $150, Earn 21.4% Annualized Using Options - Nasdaq
Charles River Laboratories International Inc Azioni (CRL) Dati Finanziari
Reddito
Reddito netto
Flusso di cassa
EPS
0.20%
0.83%
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):